

geoMapr: An analytic dashboard for prescription drug utilization with geographically referenced data enrichment and machine learning

Meilan Chen^{1,2}, Jaejoon Song¹, Yueqin Zhao¹, Yong Ma¹, Rose Radin³, Grace Chai³,

Shekhar Mehta³, Travis Ready³, Corinne Woods³, Saranrat Wittayanukorn³

¹ US Food and Drug Administration, Center for Drug Evaluation Research (CDER), Office of Translational Sciences, Division of Biometrics VII

² University of Massachusetts Amherst, Department of Mathematics and Statistics

³ US Food and Drug Administration, Center for Drug Evaluation Research (CDER), Office of Surveillance and Epidemiology, Division of Epidemiology II

Abstract

- In post-market drug safety surveillance, pharmacy dispensing data provide valuable insights to FDA of drug utilization patterns.
- We have developed a web-based interactive tool, called *geoMapr*, to analyze nationally projected data for prescription drug dispensing from a proprietary database available to the Agency.

Disclaimer

- This presentation reflects the views of the authors and should not be construed to represent FDA's views or policies.

Future Directions

- The *geoMapr* is continuously updated to address important needs in regulatory decision-making.
- A planned enhancement is to explore the feasibility of signal detection of infectious disease outbreaks related to intravenous injection of opioids.

Acknowledgements

- This research was supported by the FDA CDER *Safety Research Interest Group (SRIG)* program and by an appointment to the Research Participation Program at CDER administered by Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement between Department of Energy and FDA.

Figure 1. Home screen of *geoMapr* describes software objectives and the database.




Figure 2. Example analysis of naloxone prescriptions dispensed from U.S. from January 2014 through December 2018.



Figure 2 Note. Naloxone prescriptions dispensed from U.S. retail, mail-order/specialty pharmacies is included in the software to guide users. Current capabilities of the software include data visualization, comparison of per-capita dispensing using standardized scoring, and time series analysis. Results of this exploratory analysis can inform further investigations, as the data are not a reflection of the total use across all settings and availability of drug and do not directly measure the product's ultimate use.